Eli Lilly and Company (LLY) - Moat Analysis

Business Model

25%

3.5/5

3.47

Branded pharmaceutical revenue driven by a concentrated incretin franchise. Recurring prescription demand and long patent tails provide forward visibility, but two products (Mounjaro and Zepbound) contributed roughly 56% of FY2025 revenue, and the United States remained roughly two-thirds of that revenue. Gross margin held at 83.0% in FY2025, up from 81.3% in FY2024, reflecting high-incremental-margin branded drug economics once manufacturing capacity is in place.

Sub-dimension

Summary

Score

Revenue Predictability30%

3.50

Forward visibility of revenue: backlog, contracts, retention

3.50

Summary

Prescription refill demand in diabetes and obesity provides strong near-term visibility, and FY2026 guidance of $80-83B versus FY2025 revenue of $65.2B was issued in early 2026 with narrow range. Visibility is narrowed by single-franchise concentration and pricing volatility on realized net prices.

3.50

Product Diversification10%

2.00

Diversification across product lines, segments, and customers

2.00

Summary

Combined Mounjaro and Zepbound sales reached $36.5B in FY2025, roughly 56% of consolidated revenue, with the rest spread across Verzenio, Kisunla, Jardiance, Trulicity, Taltz, and others. Single-franchise dependence exceeds 50%, the structural condition for a low score on this axis.

2.00

Geographic Diversification15%

2.25

Distribution across regions and home-market dependence

2.25

Summary

United States revenue was $43.48B in FY2025, approximately 67% of the total, with Europe at roughly $11.6B and Japan at $2.1B. Single-country weighting in the 60-80% range means policy changes in the U.S. have outsized influence on consolidated results.

2.25

Scalability20%

4.25

Ability to grow revenue without proportional cost increases

4.25

Summary

Gross margin has remained in the low-80s across FY2021-FY2025, reaching 83.0% in FY2025, and incremental branded-drug units carry near-zero variable cost once plants are qualified. Manufacturing capex for peptide capacity is substantial but represents a one-time build rather than a structural margin cap.

4.25

Revenue Quality25%

3.50

Nature of the revenue: contractual vs transactional, defensive vs discretionary

3.50

Summary

Chronic-disease prescriptions for diabetes, obesity, oncology, and Alzheimer's are repeat-purchase and mission-critical for patients, providing durable demand above transactional norms. However, revenue is not contractual, and payer formulary placement and PBM negotiations reprice the relationship every cycle.

3.50

Competitive Advantages

40%

2.9/5

2.89

The moat rests on patented novel mechanisms and manufacturing know-how rather than network effects or switching costs. Tirzepatide has a multi-year lead in dual GIP/GLP-1 agonism with no approved direct competitor, and the pipeline extends the franchise into oral GLP-1 (orforglipron) and triple-agonism (retatrutide). Brand recognition and physician relationships support prescribing but do not stop payer repricing: U.S. Mounjaro revenue rose 57% in Q4 2025 on volume, with realized prices lower year-on-year.

Sub-dimension

Summary

Score

Pricing Power30%

2.75

The company's ability to raise prices without losing customers

2.75

Summary

2.75

Switching Costs20%

3.00

How costly it is for customers to switch to a competitor

3.00

Summary

3.00

Network Effects20%

1.50

Whether the product becomes more valuable as more users join

1.50

Summary

1.50

Brand Strength15%

3.50

Degree to which brand drives premium pricing and loyalty

3.50

Summary

3.50

Innovation Barrier15%

4.50

How difficult it is for competitors to replicate the core technology

4.50

Summary

4.50

Full analysis requires login